Profound Medical Corp.
PRN.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 8.91% | -- | -- |
| Total Other Revenue | 53.53% | -8.86% | 1.02% | 59.82% | 39.92% |
| Total Revenue | 63.89% | 39.39% | 2.69% | 59.82% | -15.09% |
| Cost of Revenue | 53.59% | 44.02% | -0.93% | 36.10% | -29.31% |
| Gross Profit | 70.38% | 36.95% | 4.62% | 89.45% | -2.75% |
| SG&A Expenses | 57.91% | 17.25% | 14.41% | 55.89% | -8.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.62% | 25.23% | 7.98% | 42.83% | -19.29% |
| Operating Income | -37.01% | -21.71% | -9.42% | -39.44% | 20.33% |
| Income Before Tax | -65.65% | 5.75% | 7.96% | 1.96% | -11.75% |
| Income Tax Expenses | 883.33% | -42.86% | -18.75% | -211.17% | -47.06% |
| Earnings from Continuing Operations | -68.30% | 5.93% | 8.04% | 6.49% | -11.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.30% | 5.93% | 8.04% | 6.49% | -11.35% |
| EBIT | -37.01% | -21.71% | -9.42% | -39.44% | 20.33% |
| EBITDA | -39.36% | -23.03% | -10.12% | -39.77% | 20.08% |
| EPS Basic | -46.15% | 18.53% | 20.83% | 8.63% | -9.14% |
| Normalized Basic EPS | -43.83% | 18.41% | 20.71% | -31.35% | -9.55% |
| EPS Diluted | -46.15% | 18.53% | 20.83% | 8.63% | -9.14% |
| Normalized Diluted EPS | -43.83% | 18.41% | 20.71% | -31.35% | -9.55% |
| Average Basic Shares Outstanding | 15.15% | 15.48% | 16.12% | 2.35% | 2.01% |
| Average Diluted Shares Outstanding | 15.15% | 15.48% | 16.12% | 2.35% | 2.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
